Treatment for Herpes Zoster Pain Using Dexmedetomidine and High Voltage Therapy
Official title: The Clinical Efficacy Analysis of Long-Duration High-Voltage Pulsed Radiofrequency Combined With Dexmedetomidine Nasal Spray in the Treatment of Herpes Zoster-Associated Neuropathic Pain
Run by Zunyi Medical College · NCT06978192 · Data updated 2026-11-12
This study is testing whether a nasal spray with dexmedetomidine, used alongside high-voltage therapy, can help people with painful herpes zoster feel better.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 40 Years to 85 Years |
| Sex | All |
| Enrollment | 92 (estimated) |
| Sponsor | Zunyi Medical College Academic / other |
| Locations | 1 site (Zunyi, Guizhou) |
| Status | Recruiting |
| Started | December 16, 2024 |
| Main results expected | February 28, 2026 |
| Study ends | May 31, 2026 |
| Registry record updated | May 18, 2025 |
| Trial ID | NCT06978192 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 40-85 with recurrent herpes zoster pain who have not responded to conventional drug treatments.
✕Probably not a fit
Patients with severe organ failure, systemic infections, or contraindications to the proposed therapies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness of dexmedetomidine nasal spray combined with long-term high-voltage pulsed radiofrequency therapy for treating pain associated with herpes zoster. Participants will be randomly assigned to either an experimental group receiving the nasal spray or a control group receiving standard treatment with high-voltage therapy. The study aims to assess pain relief and the impact on daily life for patients suffering from recurrent herpes zoster pain. Heart rate and blood pressure will be monitored throughout the treatment process.
Why it matters
Potential benefit: If successful, this treatment could significantly alleviate pain for patients suffering from herpes zoster, improving their quality of life.
How similar studies have gone: While this approach combines established treatments, the specific combination of dexmedetomidine and high-voltage therapy is novel and has not been extensively tested in previous studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with adverse reactions that are not effective in conventional drug treatment and cannot tolerate drugs * The pain is located in the corresponding innervated are * The pain affects the patient's daily life or work * Diagnostic nerve block is effective and pain limited * Recurrent herpes zoster pain * Patients with shingle-related pain aged 40-85 years Exclusion Criteria: * Infection at the puncture site, systemic infection that may spread, and malignant tumors near the puncture * There are contraindications in minimally invasive interventional therapy such as coagulation function and platelet dysfunction * Allergies to local anesthetics and inhalants * Heart, lung, liver, kidney and other important organ failure, can not tolerate surgery * Severe endocrine system diseases or long-term use of hormone or immunosuppressive therapy * Patients with cardiac pacemakers, pregnant or lactating women * Patients with cognitive dysfunction or poor coordination * Patients who have been treated with electrical stimulation or PRF
Where it's running
-
Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, China Recruiting
Study contacts
- Principal investigator: Deng — Fenghui
- Study coordinator: Fenghui Deng
- Email: 254670750@qq.com
- Phone: +8615185817588
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing Pregabalin and Lacosamide for Pain Relief in Shingles Patients
This study is testing whether Pregabalin or Lacosamide works better to relieve pain in adults aged 18 to 50 who have post-herpetic neuralgia after shingles.
-
Two-dose recombinant shingles vaccine for healthy adults 40 and older
This trial will try two doses of a recombinant shingles vaccine in healthy adults aged 40 and over to see how safe it is and whether it produces an immune response.
-
Analyzing the link between shingles and vascular dementia risk
This study is trying to see if having shingles increases the risk of developing problems with blood vessels and vascular dementia compared to people who don't have shingles.
-
Evaluating a new vaccine for shingles in adults aged 40 and older
This study is testing a new shingles vaccine in healthy adults aged 40 and older to see if it's safe and effective.
-
Evaluating the Shingrix vaccine in kidney transplant recipients
This study tests how well the Shingrix vaccine works and its safety for people waiting for a kidney transplant.
-
Recombinant Zoster Vaccine with ZFA01 Adjuvant in Adults 40+
A two-part study tests a recombinant herpes zoster vaccine in healthy adults aged 40 and older to see if it boosts immune responses and is safe.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.